Lymphoma

In a phase 1 trial, the recommended phase 2 dose of glofitamab resulted in frequent and durable complete responses for patients with follicular lymphoma and transformed diffuse large B-cell lymphoma arising from follicular lymphoma.

Combination chemotherapy treatment followed by individualized PET4-guided therapy allowed some patients with unfavorable Hodgkin lymphoma to forego radiotherapy while maintaining efficacy.

A phase 2 trial of single-agent AFM13, a bispecific tetravalent innate cell engager that binds to CD30, will continue following positive results of a preplanned interim futility analysis.

Data in The Lancet Oncology confirmed the standard of care as the optimal dosage to treat patients with indolent non-Hodgkin lymphoma.

Data from the phase 2 ZUMA-5 trial supported the approval of axicabtagene ciloleucel, a chimeric antigen receptor T-cell therapy, as a treatment for patients with follicular lymphoma in the third-line setting.

CancerNetwork® was joined by 2 clinicians from Moffitt Cancer Center to discuss why some patients do not respond to CAR T-cell therapy, despite the significant promise of the treatment modality.

Findings presented at the 2021 Transplant & Cellular Therapy Meetings indicate that patients with B-cell non-Hodgkin lymphoma may benefit from a type of natural killer immunotherapy added to chemotherapy and transplant.

A CASI press release detailed data from a phase 1/2a study examining BI-1206 in combination with rituximab to treat patients with non-Hodgkin lymphoma.

Guidelines released by the Society for Immunotherapy of Cancer are intended to provide clinicians with the most current thinking on how experts can integrate immunotherapy into the treatment of patients with lymphoma.

The approval of umbralisib was primarily based on data from the marginal zone lymphoma and follicular lymphoma patient cohorts of the phase 2b UNITY-NHL trial.

Lisocabtagene maraleucel receives FDA approval for its first indication in patients with large B-cell lymphoma.

“MRD status after both induction therapy and consolidation therapy showed prognostic value. This may provide information for deciding timing of MRD assessment,” wrote the study investigators.

Following phase 2 success, the FDA provided Bioniz Therapeutics with guidance for the design of a phase 3 trial of BNZ-1 in patients with relapsed or refractory cutaneous T-cell lymphoma.

Expert details the potential for a clinical trial using minimal residual disease to guide therapy for patients with DLBCL.

Merryman explains the value of evaluating separate transplant-related questions for patients with relapsed or refractory diffuse large B-cell lymphoma.

Thought leader detailed the findings from an oral presentation investigating patients with relapsed or refractory diffuse large B-cell lymphoma.

Crizotinib—a tyrosine kinase inhibitor with activity against ALK, ROS1, and MET—was granted FDA approval for use in pediatric patients with relapsed or refractory ALK-positive anaplastic large cell lymphoma.

Merryman provided background for the study design investigating patients with relapsed or refractory diffuse large B-cell lymphoma.

Investigators on the BRUIN trial reported impressive response rates across multiple B-cell malignancies with the use of the Bruton tyrosine kinase inhibitor LOXO-305, especially in those with heavily pretreated mantle cell lymphoma.

An expert in the treatment of diffuse large B-cell lymphoma explained some of the exciting advances in treatment and hypothesized what comes next after the 2020 ASH Annual Meeting & Exposition.

Ghobadi expressed caution about interpreting efficacy data from a phase 1 pilot study presented at the 2020 ASH Annual Meeting.

The preliminary findings of the extension arm of the phase 1b/2 GO29365 study confirmed the benefits and tolerability of polatuzumab vedotin plus bendamustine and rituximab for patients with diffuse large B-cell lymphoma.

Ghobadi detailed the next steps needed to build on the results of a study presented at the 2020 American Society of Hematology Annual Meeting & Exposition.

Extended follow up and preliminary findings from an extension cohort of the GO29365 study of polatuzumab vedotin (Polivy) for patients with diffuse large B-cell lymphoma confirmed earlier reports of efficacy and safety, and demonstrated continued deepening responses.

Ghobadi explained an interesting correlation found in the results of his study presented at the 2020 ASH Annual Meeting & Exposition.